Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Onglyza

- PMLiVE

Boehringer spends €1.18bn to acquire NBE-Therapeutics

Company specialises in antibody-drug conjugate development

- PMLiVE

FDA expert panel recommends EUA for Pfizer/BioNTech COVID-19 vaccine

Formal approval in the US could follow 'within days'

- PMLiVE

FDA briefing document paves the way for Pfizer/BioNTech COVID-19 vaccine approval

Advisory Committee is set to meet today to discuss vaccine's safety and efficacy data

- PMLiVE

The Lancet confirms effectiveness of AZ/Oxford University’s COVID-19 vaccine

Final average efficacy analysis found to be 70.4%

- PMLiVE

US secures 650,000 additional doses of Lilly’s COVID-19 antibody

This takes the total purchased amount to 950,000 doses

- PMLiVE

Novavax moves closer toward launch of US phase 3 COVID-19 vaccine trial

Company also completes enrolment in UK-based phase 3 trial

- PMLiVE

AZ divests European rights for cholesterol med Crestor to Grünenthal

Grünenthal will pay up to $350m for the rights

- PMLiVE

AZ, Oxford University face more scrutiny over COVID-19 vaccine data

WHO’s immunisations director says ‘more than a press release’ is needed

Roche Basel Switzerland

Roche’s Xofluza pill wins FDA approval for post-exposure flu prevention

First single-dose flu medication approved for post-exposure prophylaxis

- PMLiVE

FDA sets 10 December date for Pfizer’s COVID-19 vaccine meeting

Independent experts will discuss EUA submission for mRNA-based vaccine

- PMLiVE

Lilly links up with Precision BioSciences in genome editing deal

Precision will receive an upfront cash payment of $100m

regeneron headquarters

Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval

Drug approved to treat high-risk patients with mild to moderate COVID-19

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links